Article
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Sept 2016
Feld Jordan J, Maan Raoel, Zeuzem Stefan, Kuo Alexander, Nelson David R, Di Bisceglie Adrian M, Manns Michael P, Sherman Ken, Frazier Lynn M, Sterling Richard, Mailliard Mark, Schmidt Monica, Akushevich Lucy, Vainorius Monika, Fried Michael W
Abstract excerpt
BACKGROUND: Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study reports the effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.